Company
Kezar Life Sciences, Inc. (KZR)
Standardized SEC financial data for Kezar Life Sciences, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001645666 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-80.0%
Free cash flow
-$51.8M
Debt / equity
0.00×
Current ratio
11.52×
EPS (diluted)
$-7.66
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $7.0M | $0 | $0 |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.2M | $62.9M | $40.5M | $35.5M | $132.2M | $71.9M |
| Total current assets |
Get KZR data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/KZR/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/KZR/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"